Formulation Development and Evaluation of Floating Microbaloons of Ziprasidone Hydrochloride by Lakshmi Srujana, Ch
1FORMULATION DEVELOPMENT AND EVALUATION OF FLOATING    
MICROBALOONS OF ZIPRASIDONE HYDROCHLORIDE
Dissertation submitted to
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY, CHENNAI-32
In partial fulfillment for the award of the degree of
MASTER OF PHARMACY
                                                                IN
PHARMACEUTICS
Submitted by
Register Number: 26111010
UNDER THE GUIDANCE OF
Dr. Vinay Rao, M.Pharm., PhD.      Mr. T. UdayaKumar, M.Pharm.
               (Industrial Guide)                                              (Institutional Guide)
                                    DEPARTMENT OF PHARMACEUTICS,
C.L.BAID METHA COLLEGE OF PHARMACY,
(AN ISO 9001-2000 certified institute)
THORAIPAKKAM, CHENNAI-600097
  APRIL-2013
2CERTIFICATE
                    This is to certify that the dissertation work entitled “FORMULATION 
DEVELOPMENT AND EVALUATION OF FLOATING MICROBALOONS OF 
ZIPRASIDONE HYDROCHLORIDE” submitted to THE TAMILNADU DR. M. G. 
R. MEDICAL UNIVERSITY, CHENNAI-32 for the award of the degree Master of 
pharmacy in Pharmaceutics is a bonafide research work done by Register Number: 
26111010 under my Guidance in the Department of Pharmaceutics, C.L. Baid Metha 
College of Pharmacy, Chennai-600097 during the academic year 2012-2013.
                                                                    
Place: Chennai-97.                                         Mr . T.UDAYAKUMAR, M.pharm.,
Date:                                                                             Assistant professor,
                                                                                Department of pharmaceutics,
                                                                         C.L.Baid Metha college of pharmacy,
                                                                                             Chennai-97.
3                                                                                                                             
Prof . Dr . Grace Rathnam, M.pharm., PhD
Principal,
CERTIFICATE
                     This is to certify that the dissertation work entitled “FORMULATION 
DEVELOPMENT AND EVALUATION OF FLOATING MICROBALOONS OF 
ZIPRASIDONE HYDROCHLORIDE” submitted to THE TAMILNADU DR. M. G. 
R. MEDICAL UNIVERSITY, CHENNAI-32 for the award of the degree Master of 
Pharmacy in Pharmaceutics is a bonafide research work done by Register 
Number:26111010 under the  guidance of Mr.T.UDAYAKUMAR M.Pharm., 
Assistant professor, Department of Pharmaceutics, C. L. Baid Metha college of 
Pharmacy, Chennai-600097 during the academic year 2012-2013.
Place: Chennai -97.                   Prof. Dr. GRACE RATHNAM, M. Pharm., Ph.D.,
Date:             Principal  & HOD,                          
                                                                 Department of Pharmaceutics,                             
                                                              C.L.Baid Metha college of Pharmacy,                                  
                                                                             Chennai-97.
4
5DECLARATION
                     I hereby declare that the thesis entitled “FORMULATION 
DEVELOPMENT AND EVALUATION OF FLOATING MICROBALOONS OF 
ZIPRASIDONE HYDROCHLORIDE” has been originally carried out by me under the 
supervision and guidance of Dr.Vinay Rao,M.Pharm.,Ph.D(Industrial Guide)and 
Mr.T.Udayakumar,M.Pharm. (Institutional Guide) Asst. Professor, Department of 
pharmaceutics, C.L.Baid Metha College of pharmacy Chennai-97 during the academic 
year 2012-2013. 
Place: Chennai-97.                                            Register Number: 26111010,                            
Date:                                                                Department of Pharmaceutics,
                                                                       C.L.Baid Metha college of Pharmacy,
                                                                                  Chennai-97.                                                                                                                             
6ABBREVIATIONS
API Active Pharmaceutical Ingredient
CDDS Controlled Drug Delivery Systems
CI Compressibility Index
CRDF Controlled Release Dosage Forms
DMSO Dimethylsulphoxide
DNA Deoxy Ribo nucleic acid
DOE Design Of Experiments
EC Ethyl Cellulose
FDDS Floating Drug Delivery Systems
FTIR Fourier Transformer Infrared Spectroscopy
GIT Gastro Intestinal Tract
GRDF Gastro Retentive Dosage Form
GRT Gastric Retention Time
HBS Hydrodynamically Balanced system
HCL Hydrochloric  Acid
HPMC Hydroxy Propyl Methyl Cellulose
HR Hausner Ratio
IP Indian Pharmacopoeia
IPA Isopropyl Alcohol 
MMC Migrating Mylo Electricitycycle
PVA Poly Vinyl Alcohol
RH Relative Humidity
USP United States Pharmacopoeia
WHO World Health Organisation 
7NOMENCLATURE
% Percentage
µg/ml Microgram/millilitre
Conc Concentration
gm/cc Gram/cubic centimetre
Hr Hour
Kg/cm2 Kilogram/square centimetre
Min Minute
Mm Millimetre
Ng Nanogram
ng/ml Nanogram/millilitre
ng-hr/ml Nanogram-hour/millilitre
Sec Seconds
8Sl.No TABLE NAME PAGE 
NUMBER
1 TRANSIT TIME OF VARIOUS DOSAGE FORMS 8
2 MARKETED PREPARATIONS OF FDDS 23
3 LIST OF MATERIALS AND THEIR SUPPLIERS 44
4 LIST OF EQUIPMENTS 44
5 FULL FACTORIAL DOE OF FLOATING MICRO 
CAPSULES
49
6 DESIGN OF EXPERIMENTS 49
7 CALIBRATION VALUES IF ZIPRASIDONE HYDRO 
CHLORIDE
58
8 PERCENTAGE YIELD OF FORMULATIONS 59
9 MEAN PARTICLE SIZE OF THE MICROCAPSULES OF 
THE FORMULATIONS
60
10 ENTRAPMENT EFFICIENCIES OF THE 
FORMULATIONS
63
11 INVITRO BUOYANCY STUDIES 65
12 DISSSOLUTION PROFILE AT PH1.2 67
13 RELEASE EXPONENT VALUES AND DRUG 
TRANSPORT MECHANISM
69
14 RELEASE RATE OF ZIPRASIDONE HYDROCHLORIDE 
FROM FORMULATIONS(F1-F8)
70
15 DESIGN SPACE RANGE FOR ENTRAPMENT 
EFFICIENCY
77
16 COMPOSITION AND ENTRAPMENT EFFICIENCY OF 
OPTIMIZED FORMULATIONS
78
17 DISSOLUTION PROFILE FOR OPTIMIZED 
FORMULATION
79
18 RELEASE RATE OF ZIPRASIDONE HYDROCHLORIDE 
FROM OPTIMIZED FORMULATIONS
80
19 ACCELERATED STABILITY STUDIES FOR 
ZIPRASIDONE HYDROCHLORIDE
83
20 ASSAY AND INVITRO DISSSOLUTION TESTING 84
9S.NO TITLE PAGE 
NUMBER
1 PLASMA LEVEL PROFILES 2
2 COMPARISON OF CONVENTIONAL DOSAGE FORM 
AND GASTRO RETENTIVE DOSAGE FORM
3
3 ANATOMY OF STOMACH 4
4 STRUCTURE OF THE STOMACH 5
5 MOTILITY PATTERNS OF THE GIT IN THE FASTED 
STATE
6
6 FLOW CHART ENLISTING VARIOUS APPROACHES 
USED FOR DESIGNING FDDS
11
7 COLLOIDAL GEL BARRIER FLOATING TABLETS 14
8 BILAYER INTRA GASTRIC FLOATING TABLETS 15
9 MICROPOROUS INTRA GASTRIC FDDS 16
10 DIFFUSION METHOD MECHANISM OF MICRO 
BALLON FORMULATION
17
11 GASTRO INFLATABLE DRUG DELIVERY DEVICE 18
12 INTRA GASTRIC OSMOTIC CONTROLLED DRUG 
DELIVERY SYSTEM
19
13 MULTIPLE UNIT ORAL FLOATING DOSAGE SYSTEM 20
14 MECHANISM OF EFFERVESCENT DRUG DELIVERY 
SYSTEM
20
15 PHOTOGRAPHS OF THE FORMULATIONS OF HIGH 
ENTRAPMENT EFFICIENCY
50
16 FTIR OF ZIPRASIDONE HYDRO CHLORIDE 57
17 FTIR OF OPTIMIZED FORMULATION 57
18 CALIBRATION CURVE OF ZIPRASIDONE 58
19 MEAN  PARTICLE  SIZE OF THE MICROCAPSULES 61
20 SCANNING ELECTRON MICROSCOPY OF BLANK 
MICROCAPSULES
62
21 SCANNING ELECTRON MICROSCOPY OF FOPTIMA 1 62
22 SCANNING ELECTRON MICROSCOPY OF FOPTIMA2 62
23 ENTRAPMENT EFFICIENCY 64
24 DISSOLUTION PROFILE OF ZIPRASIDONE 
HYDROCHLORIDE
68
25 DESIGN OF EXPERIMENTS 72
26 DISSOLUTION PROFILE FOR OPTIMIZED 
FORMULATIONS
79
27 RELEASE RATE ZIPRASIDONE HYDROCHLORIDE 
FROM FOPTIMA 1
81
28 RELEASE RATE ZIPRASIDONE HYDROCHLORIDE 
FROM FOPTIMA 2
81
29 RELEASE RATE ZIPRASIDONE HYDROCHLORIDE 
FROM FOPTIMA 3
82
10
ACKNOWLEDGEMENT
It is a great time for me to acknowledge those without whom, this work would not 
have been fruitful.
It gives me an immense pleasure in expressing my deep sense of gratitude to my  
respected  guide  Mr. T.UDAYAKUMAR  M. Pharm., Assistant professor, C.L.Baid  
Metha college of pharmacy,Chennai-97 for his remarkable guidance, constant 
encouragement and every scientific  and  personal  concern  throughout  the  course  of  
investigation  and successful completion of this work.
I would like to express my immense gratitude to my industrial guide 
Dr VINAY RAO. , M.Pharm, Ph.D.for providing the great opportunity to carry out the 
project in Medreich Limited, Bangalore-33, for his valuable guidance and support in 
each and every aspect of the project.
         It is great pleasure and honour for me to owe gratitude to Dr. Grace Rathnam 
M.Pharm, Ph.D. principal for all her support and for giving a valuable guidance and 
scientific support to carry out this work.
I would like to thank Medreich Limited, Bangalore-33, for giving me an 
opportunity to perform my project work in their organization which helped me to mould 
my project work into a successful one.
I feel proud to express my hearty gratitude and appreciation to all my Teaching 
and Non-teaching Staff members of C.L.Baid Metha College of Pharmacy, Chennai-
97 who encouraged to complete this work.
11
             I feel proud to express my hearty gratitude to all my classmates. Also I want to 
thank all of those, whom I may not be able to name individually, for helping me directly 
or indirectly.
Last but not the least I wish to express my deepest sense to respect and love to my 
parents for their constant support and encouragement throughout.
(Register  Number: 26111010)
12
CONTENTS
Chapter No. TITLE Page No.
1 Introduction 1
2 Literature Review 24
3 Aim and Objective 30
4 Plan of Work 31
5 Drug and Excipient Profile 32
6 Materials and Methods 44
7 Results and Discussions 56
8 Summary and Conclusion 84
9 Bibiliography 86
13
1. INTRODUCTION
1.1 Oral Controlled Drug Delivery System: 1
             Oral controlled release dosage forms (CRDF) have been extensively used 
to improve therapy of many important medications. The design of oral controlled drug 
delivery systems (CDDS) should primarily be aimed at achieving more predictable and 
increased bioavailability of drugs. 
                        However, the developmental process is precluded by several physiological 
difficulties, such as inability to restrain and locate the CDDS within desired regions of 
gastrointestinal tract (GIT) due to the variable gastric emptying and motility. 
                        The variability may lead to unpredictable time for peak plasma levels and 
bioavailability. Therefore, the CRDF approaches has not been suitable for a variety of 
important drugs, characterized by a narrow absorption window in the upper part of the 
GIT, i.e. stomach and small intestine, which is due to relatively short transit time of the 
dosage form in these anatomical segments. 
                         Thus within a short period (less than 6 hours), the CRDF of such drugs 
leave the upper part of GIT and reaches to the non-absorbing distal segment, eventually 
resulting in a short absorption phase accompanied with lesser bioavailability.
            Invariably, conventional dosage forms do not maintain the drug blood 
levels within the therapeutic range for an extended period of time. To achieve the same, a 
drug may be administered repeatedly using a fixed dosing interval. This causes several 
potential problems like saw tooth kinetics characterized by large peaks and troughs in the 
drug concentration-time curve in Figure 1
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Figure 1: Plasma level profiles following conventional and controlled release dosing
          
                      The relatively brief gastric emptying time in humans normally averages 2
to 3 hours. through the major absorption zone (stomach or upper part of the intestine), 
which can result in incomplete drug release from the drug delivery system leading to 
diminished efficacy of the administered dose. 
                        Thus, placement of the drug delivery system in a specific region of the 
GIT offers numerous advantages, especially to the drugs having narrow absorption 
window in GIT, primary absorption in the stomach, stability problem in intestine, poor 
solubility at alkaline pH, local activity in stomach and property to degrade in colon.              
Compounding the drugs with narrow absorption window in a unique pharmaceutical 
dosage form, which prolongs the gastric residence time would enable an extended 
absorption phase of these drugs.
           One of the most feasible approaches for achieving a prolonged and 
predictable drug delivery profiles in the GIT is to control the gastric residence time, using 
gastro-retentive dosage forms (GRDF). GRDF are the drug delivery systems that are 
designed to be retained in the stomach for a prolonged time and release their active 
materials and thereby enable sustained input of the drug to the upper part of the GIT. 
                        This technology has generated enormous attention over the last few 
decades owing to its potential application to improve the oral delivery of some important 
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drugs for which prolonged retention in the upper GIT can greatly improve their oral 
bioavailability and/or their therapeutic outcome in Figure 2
       
Figure 2:Comparison of conventional dosage form and gastro retentive dosage form
             In the last three decades various attempts have been made to develop a 
novel and efficient gastro-retentive dosage forms which can retain in the stomach for an 
extended period of time in a predetermined manner.
                         This can be achieved by improving scientific and technological 
advancement to overcome physiological problems like pH of the stomach, motility and 
gastric emptying time by altering physiological and formulation variables. Many 
approaches are utilized in the development of gastric retention drug delivery systems viz., 
floating systems, swelling, expanding, high density, super porous hydrogels, bioadhesive, 
modified shape systems, ion exchange resin and by the simultaneous administration of 
pharmacological agents that delay gastric emptying. By utilizing one of these techniques 
it is possible to deliver drugs that have narrow absorption window. 
              From the formulation and technological point of view, the floating drug 
delivery system (FDDS) is considerably easy and logical approach in the development of 
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GRDF. Floating drug delivery system float on the gastric fluid only when it has density 
less than that of gastric fluids, i.e. <1g/cm3. Usually, floating formulations are prepared 
from hydrophilic matrices that either have a density lower than one or their density drops 
below one after immersion in the gastric fluids owing to swelling.
                          More sophisticated devices are developed later and involved the use of 
various film coating techniques, incorporation of a floating chamber that is filled with 
harmless gas, or a liquid that gasifies at body temperature.
                          These systems are often called hydro-dynamically balanced system as 
they can maintain low density and keep floating even after hydrating. This system 
provides several advantages as prolonged gastric retention of drugs, improves 
bioavailability, reduces drug wastage and improves solubility for drugs that are less 
soluble in alkaline pH environment and provides local drug delivery to the stomach and 
proximal small intestine.
1.2 Basic physiology of stomach2:
                           The stomach is a ‘J’ shaped enlargement of the GI tract directly inferior 
to the diaphragm in the epigastric, umbilical and left hypochondria regions of the 
abdomen. The stomach connects the esophagus to the duodenum, the first part of the 
small intestine. Anatomy of stomach is shown in Figure 3.
Figure 3: Anatomy of stomach
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                    The stomach lies between the esophagus (proximally) and the duodenum 
(distally). It varies widely in size and shape depending on the person, the food content, 
and the posture of the body. It is J-shaped normally and the pyloric part lies horizontally 
or ascends to meet the proximal part of the duodenum. 
Figure 4: Structure of the stomach
Anatomically the stomach is divided into 3 regions: 
 Fundus: The superior part of the stomach, this lies above the imaginary horizontal 
plane passing through the cardiac orifice.
 Body: This lies between the fundus and the antrum, and it is the largest part of the 
stomach.
 Antrum: This lies in the imaginary transpyloric plane and to the right of the 
angular notch. It joins the pyloric canal on its right.
                    The main function of fundus and body is storage whereas that of antrum 
is mixing or grinding. The fundus adjusts to the increased volume during eating by 
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relaxation of the fundus muscle fibers. The fundus also exerts a steady pressure on the 
gastric contents, pressing them towards the distal stomach. To pass through the pyloric 
valve into the small intestine, particles should be of the order of 1 to 2 mm. The antrum 
does this grinding. The stomach has limitation of short residence time.
1.3 Gastric Motility3:  
                        The pattern of motility is distinct in fasted and fed states. During 
the fasting state an inter digestive series of electrical events takes place, which cycle both 
through stomach and intestine every 2 to 3 hrs. This is called the interdigestive 
myloelectric cycle or migrating myloelectric cycle, which is divided into following 4 
phases.
   
Figure 5:  Motility Patterns of the GIT in the Fasted State
 Phase I (basal):
                       Lasts for 30 to 60 minutes. With rare contractions and is characterized                
by a lack of secretary, electrical, and contractile activity.
 Phase II (preburst):
        Lasts for 20 to 40 minutes. with intermittent action potential and 
contractions.
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 Phase III (burst):
                 Lasts for 10 to 20 minutes. Includes intense and regular 
contractions. It is due to this wave that all undigested material is swept out of 
the stomach down to the small intestine. It is also known as housekeeper 
wave.
 Phase IV: 
            Lasts for 0 to 5 minutes.
              After the ingestion of a mixed meal, the pattern of contractions changes 
from fasted to fed state. It comprises continuous contractions as in phase II of fasted 
state. These contractions result in reducing the size of food particles (<1mm), which are 
propelled towards pylorus. During fed state onset of MMC is delayed resulting in 
slowdown of gastric emptying rate.
1.4 Gastric Emptying1,3:
             It can be anticipated that, depending upon the physiological state of 
subject and design of pharmaceutical formulation, the emptying process last from a few 
minute to 12 hours.
             Furthermore the relatively brief gastric emptying time in humans which 
normally averages 2 to 3 hours through the major absorption zone (stomach or upper part 
of intestine). Particle size and feeding state strongly affect the residence time of particles 
in the stomach.
           Some other factors affecting gastric emptying are type of meal and its 
caloric content, volume, viscosity and co-administered drugs. The rate of gastric 
emptying primarily depends on the caloric contents of the ingested meal. It does not 
differ for proteins, fats, and carbohydrates as long as their caloric content is the same.           
Generally an increase in acidity, osmolarity and caloric value slows down gastric 
emptying. 
              Stress increases gastric emptying rate whereas depression slows it down. 
Females have a slower gastric emptying rate than males. Age and obesity also affect 
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gastric emptying. Gastric emptying of dosage forms is different in fasted and fed 
conditions. 
Table 1: Transit time of various dosage forms across the segments of the
               Gastro Intestinal Tract
Dosage forms
Transit time (hours) 
Stomach Small intestine Total
Tablets 2.7 3.1 5.8
Pellets 1.2 3.4 4.6
Capsules 0.8 3.2 4.0
Solution 0.3 4.1 4.4
1.5 Factors affecting gastric emptying time4:
1.5.1 Volume:
        The resting volume of stomach is about 25 to 52 ml. This volume is 
important for dissolution of dosage forms. As the volume is large, emptying is faster. 
Gastric emptying of small volumes like 100 ml or less is governed by MMC cycle 
whereas large volumes of liquids like 200 ml or more are emptied out immediately after 
administration. Fluids at body temperature leave the stomach more rapidly than either 
warmer or colder fluids.  
1.5.2 Hormonal Effects: 
                Stress conditions increases gastric emptying rate whereas depression 
slows down gastric emptying time. Generally females have slower gastric emptying rate 
than males. Age and obesity also affect gastric emptying.
1.5.3 Presence of Food: 
                 Gastric emptying time differs in fasted state and in fed state. The caloric 
value of food affects the gastric emptying time.
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1.5.4 Gastric Secretions: 
                Acids, pepsin, gastrin, mucus and other enzymes are the secretions of 
stomach. Normal adults produce a basal secretion upto 60 ml with approximately  4 
millimoles of hydrogen ions every hour. 
1.6. Factors affecting gastric residence time of dosage form5                                                                           
1.6.1 Density: 
        Gastric residence time increases if the density of the dosage form is less than 
the gastric contents (<1.004 gm/ml). 
1.6.2 Size and Shape:
        Small-size tablets leave the stomach during the digestive phase while the 
large size tablets are emptied during the housekeeping waves.
1.6.3 Fed or Unfed state: 
              Under fasting conditions, the GI motility is characterized by periods of 
MMC that occurs every 1.5 to 2 hours. The MMC sweeps undigested material from the 
stomach and if the timing of administration of the formulation coincides with that of the 
MMC, the gastric residence time of the unit can be expected to be very short. However, 
in the fed state, MMC is delayed and gastric residence time is considerably longer.
1.6.4 Frequency of Feed: 
             The gastric residence time can be increased by over 400 minutes when 
successive meals are given compared with a single meal due to the low frequency of 
MMC.
1.6.5 Posture: 
             Gastric residence time can vary between supine and upright ambulatory 
state of the patients.
1.6.6 Concomitant drug administration:
             Anticholinergics like atropine and propentheline, opioids like codeine and 
prokinetic agents like metoclopromide and cisapride affects the GRT when administered 
together.
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1.6.7 Biological Factors:
            Diabetes and Crohn’s disease also affects gastric residence time. 
1.7.Formulation approaches for gastro retentive drug delivery systems  
(GRDDS)6      
               
               There are several formulation approaches used for designing GRDDS. 
These include Swelling and Expanding system, which are retained in the gastric region 
due to their large size gained after swelling.
                Floating system are retained in the gastric region due to their floating 
ability on the gastric fluid. The floating system is further divided into single unit system 
such as floating tablets and multiparticulate systems such as floating microspheres, which 
offer more advantages as compared to single unit system.
               The floating system is further divided into effervescent and non-
effervescent floating system based on their mechanism of floating. Bioadhesive systems 
adhere to the gastric mucosa due to which they are retained in the gastric region.
                High density system are retained due to their increased density then the
gastric fluid. Beside this, passage delaying food as well as drugs can be administered 
simultaneously to retain the dosage form in the gastric region.
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The Flowchart shows the various approaches used to retain the dosage forms 
in the gastric region.
GRDDS
Swelling and Floating System                   Bioadhesive Systems             High-Density 
Expanding Systems                             Systems
           Single Unit Systems                 Multiparticulate Systems
Effervescent Non-Effervescent Effervescent Non- Effervescent
Gas generating                Low density polymers       Microparticles                Waxy Microparticles
Excipients in gel   (Hydrophilic & Microballons                 Alginate beads
Forming polymers Hydrophobic) Pellets, Beads                 Foam powder 
Figure 6: Flowchart enlisting various approaches used for designing FDDS
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1.7.1 Swelling and Expanding systems:
                   Swelling type dosage forms are such that after swallowing, these 
products swell to an extent that prevents their exit from the stomach through the pylorus. 
As a result, the dosage form is retained in the stomach for a long period of time. These 
systems may be referred to as ‘plug type’ systems since they exhibit tendency to remain 
lodged at the pyloric sphincter.
1.7.2 Floating System (Low Density Approach): 
                    These systems are also known as hydro-dynamically balanced 
systems. (HBS/FDDS) They have a bulk density lower than gastric fluid, i.e. their bulk 
density is less than one. The specific gravity of gastric fluid is approximately 1.004 to 
1.010 g/cm3 and thus the FDDS remains buoyant in the stomach without affecting the 
gastric emptying rate for a prolonged period of time. While the system is floating on the 
gastric contents the drug is released slowly at a desired rate from the system. After the 
release of the drug the residual system is emptied from the stomach.
1.7.3 Bioadhesive Systems:
                 They are used to localize a delivery device within the lumen and cavity 
of the body to enhance the drug absorption process in a site-specific manner. It makes use 
of bioadhesive polymers. These polymers tend to form hydrogen and electrostatic bonds 
at the mucus polymer boundary.
1.7.4 High Density Systems: 
                  High density formulations include coated pellets that have density 
greater than that of stomach contents. (>1.004g/cm3) This is accomplished by coating the 
drug with heavy inert materials such as Barium sulfate, Titanium dioxide, Iron powder or 
oxide. The weighted pellet can then be covered with a diffusion-controlling polymer 
membrane.
1.7.5.Modified Shape Systems: 
                 These are non-disintegrating geometric shapes molded from silastic 
elastomer or extruded from polyethylene blends which extend the gastric residence time 
depending on size and shape of the dosage form
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1.7.6.Use of other delayed gastric emptying devices: 
                 It includes feeding of indigestible polymers or fatty acid salts that 
change the motility pattern of the stomach to a fed state, thereby decreasing the gastric 
emptying rate and permitting considerable prolongation of drug release.
1.7.7.Osmotic regulated system: 
                  It is comprised of an osmotic pressure controlled drug delivery device 
and an inflatable floating support in a bioerodible capsule. In the stomach the capsule 
quickly disintegrates to release the intragastric osmotically controlled drug delivery 
device. The inflatable support inside forms a deformable hollow polymeric bag that 
contains a liquid that gasifies at body temperature to inflate the bag. The osmotic pressure 
controlled drug delivery device consists of two components are as: drug reservoir 
compartment and osmotically active compartment.
Incorporation of passage delaying food agents: 
                 The food excipients like fatty acids, e.g. salts of Myrestic acid change 
and modify the pattern of the stomach to a fed state, there by decreasing gastric emptying
rate and permitting considerable prolongation of release. The delay in the gastric 
emptying after meals rich in fats is largely caused by saturated fatty acids with chain 
length of C10 to C14.
1.7.8.Ion exchange resin: 
                  A coated ion exchange resin bead formulation has been shown to have 
gastric retentive properties, which was loaded with bicarbonates. Ion exchange resins are 
loaded with bicarbonate and a negatively charged drug is bound to the resin, resultant 
beads were then encapsulated in a semi-permeable membrane to overcome the rapid loss 
of carbon dioxide. Upon arrival in the acidic environment of the stomach and exchange 
of chloride and bicarbonate ions take place. As a result of this reaction carbon dioxide 
was released and trapped in a membrane thereby carrying beads towards the top of gastric 
content and producing a floating layer of resin beads in contrast the uncoated beads, 
which will sink quickly.
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1.8.Design and fabrication of Floating drug delivery system (FDDS)4,5
1.8.1 Non - Effervescent FDDS
1.8.1.1 Colloidal gel barrier system:
                   HBS of this type contains drug with gel forming or swellable cellulose 
type hydrocolloids, polysaccharides and matrix forming polymers. They help prolonging 
the GI residence time and maximize drug reaching its absorption site in the solution form 
ready for absorption.
           These systems incorporate high levels (20 to 75 % w/w) of one or more 
gel forming highly swellable cellulose type hydrocolloids e.g. Hydroxyl Ethyl Cellulose,    
Hydroxy Propyl Cellulose, Hydroxy Propyl Methyl Cellulose, Sodium Carboxy Methyl
Cellulose, Polysaccharides and matrix forming polymers such as Polycarbophil, 
Polyacrylates and polystyrene incorporated either in tablets or capsules. 
                 When such a system comes in contact with the gastric fluid, the 
hydrochloride in the system hydrates and forms a colloidal gel barrier around its surface. 
The air trapped inside the swollen polymer maintains the density less than unity and 
confers buoyancy to these dosage forms. This gel barrier controls the rate of the fluid 
penetration into the device and consequent release of drug from it.
                    
Figure 7: Colloidal gel barrier floating tablet
The HBS must comply with following three major criteria:
 It must have sufficient structure to form cohesive gel barrier.
 It must maintain specific density lower than that of gastric contents.          
 It should dissolve slowly to serve as reservoir for the delivery system.
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              A bilayer tablet can also be prepared to contain one immediate release 
and other sustained release layer. Immediate release layer delivers the initial dose 
whereas sustained release layer absorbs gastric fluid and forms a colloidal gel barrier on 
its surface. This results in system with bulk density lesser than that of gastric fluid and 
allows it to remain buoyant in the stomach for an extended period of time.
              A multi-layer, sheath-like device buoyant in gastric juice showing 
sustained release characteristics has also been developed. The device consists of at least 
one dry self-supporting carrier film made up of water insoluble polymer matrix having a 
drug dispersed/dissolved therein, and a barrier film overlaying the carrier film. Both 
carrier and barrier films are sealed together along their periphery and in such a way as to 
entrap a plurality of small air pockets, which bring about the buoyancy to the laminated 
films.
Figure 8: Bilayer intra-gastric Floating tablet
1.8.1.2 Micro-porous compartment system:
                   This technology is comprised of encapsulation of a drug reservoir 
inside a micro-porous compartment with pores along its top and bottom surfaces. The 
Sustained Release Layer
     (Hydrocolloids) Colloidal Gel Barrier
Sustained release layer
Immediate Release Layer
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peripheral walls of the drug reservoir compartment are completely sealed to prevent any 
direct contact of gastric mucosal surface with undissolved drug.
               In stomach, the floatation chamber containing entrapped air causes the 
delivery system to float over the gastric contents. Gastric fluid enters through the pores, 
dissolves the drug and carries the dissolved drug for continuous transport across the 
intestine for absorption.
Figure 9:  Micro-porous intra-gastric FDDS
1.8.1.3 Alginate beads:
                   Multiple unit floating dosage forms have been developed from freeze-
dried calcium alginate. Spherical beads of approximately 2.5 mm in diameter were 
prepared by dropping a sodium alginate solution into aqueous solution of calcium 
chloride, causing a precipitation of calcium alginate. These beads were then separated, 
snap frozen in liquid nitrogen and freeze-dried at 400C for 24 hours, leading to formation 
of porous system that maintained floating force for over 12 hours. They were compared 
with non-floating solid beads of same material. The latter gave a short residence time of 1 
hour, while floating beads gave a prolonged residence time of more than 5.5 hours.
                   Floating systems comprising of calcium alginate core separated by an 
air compartment from a membrane of calcium alginate or a calcium alginate/polyvinyl 
alcohol (PVA) have also been developed. The porous structure generated by leaching of 
PVA (water soluble additive in coating composition) was found to increase membrane 
permeability and thus preventing the collapse of air compartment.
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1.8.1.4 Hollow Microspheres:
                  Hollow microspheres (micro-balloons) loaded with Ibuprofen in their 
outer polymer shells were prepared by novel emulsion solvent diffusion method. The 
Ethanol:Dichloromethane solution of the drug and an enteric acrylic polymer were 
poured into an agitated aqueous solution of PVA that was thermally controlled at 40o C. 
The gas phase was generated in dispersed polymer droplet by evaporation of 
dichloromethane and formed an internal cavity in microsphere of polymer with drug. 
These micro-balloons floated continuously over surface of acidic solution media that 
contained surfactant, for greater than 12 hours In-vitro. The drug release was high in pH 
7.2 than in pH 6.8.
Figure 10:Diffusion method-Mechanism of Micro-Balloon formation by 
                             Emulsion-solvent              
1.8.1 Effervescent systems:
                A drug delivery system can be made to float in the stomach by 
incorporating a floating chamber, which may be filled with vacuum, air or inert gas. The 
gas in floating chamber can be introduced either by volatilization of an organic solvent 
or by effervescent reaction between organic acids and bicarbonate salts.
1.8.2.1 Volatile Liquid containing systems:
                         The GRT of a drug delivery system can be sustained by 
incorporating an inflatable chamber which contains a liquid e.g. Ether or Cyclo-pentane 
that gasifies at body temperature to cause the inflation of the chamber in the stomach. 
These devices are osmotically controlled floating systems containing a hollow 
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deformable unit that can be converted from a collapsed to an expanded position and 
returned to collapsed position after an extended period. A deformable system consists of 
two chambers separated by an impermeable, pressure responsive, movable bladder. The 
first chamber contains the drug and the second chamber contains volatile liquid. The 
device inflates and the drug is continuously released from the reservoir into the gastric 
fluid. The device may also consist of bioerodible plug made up of PVA, Polyethylene, 
etc. that gradually dissolves causing the inflatable chamber to release gas and collapse 
after a predetermined time to permit the spontaneous ejection of the inflatable system 
from the stomach.
Figure 11: Gastro inflatable drug delivery device
                    
                     Intra-gastric, osmotically controlled drug delivery system consists of an 
osmotic pressure controlled drug delivery device and an inflatable floating support in 
bioerodible capsule.
         When the device reaches the stomach, bioerodible capsule quickly 
disintegrates to release the drug delivery system. The floating support is made up of a 
deformable hollow polymeric bag containing a liquid that gasifies at body temperature to 
inflate the bag.
            The osmotic pressure controlled part consists of two compartments, a drug 
reservoir compartment, and an osmotically active agent-containing compartment. The 
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drug reservoir compartment is enclosed in a pressure responsive collapsible bag, which is 
impermeable to vapors and liquid, and has a drug delivery orifice. 
             The osmotic compartment contains an osmotically active salt, and is 
enclosed within semi-permeable housing. In stomach, water is absorbed through the 
semi-permeable membrane into the osmotic compartment to dissolve the salt.
            An osmotic pressure thus created acts on collapsible bag and in turn 
forces the drug reservoir compartment to reduce its volume and release the drug solution 
through the delivery orifice. The floating support also contains a bioerodible plug that 
erodes after a predetermined time to deflate the support, which is then excreted from the 
stomach.
Figure 12:  Intragastric osmotic controlled drug delivery system
1.8.2.2 Gas generating systems:
                  These buoyant delivery systems utilize effervescent reaction between 
carbonate/bicarbonate salts and citric/tartaric acid to liberate Carbon-di-oxide which gets 
entrapped in the jellified hydrochloride layer of the system, thus decreasing its specific 
gravity and making it float over chyme. Multiple unit type of floating pills that generate 
Carbon-di-oxide also has been developed. The system consists of sustained release pill as 
a seed, surrounded by double layer. The inner layer is an effervescent layer containing 
sodium bicarbonate and tartaric acid. The outer layer is swellable membrane layer. These 
kinds of systems float completely within 10 minutes and remain floating over an 
extended period of 6 to 24 hours
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Figure 13:Multiple unit oral Floating dosage systems
Following figure shows mechanism of Floating of Effervescent drug delivery system:
Figure 14:  Mechanism of Effervescent drug delivery system
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1.8.2 Recent advances in FDDS:
1.8.3.1 Floating multi-layer coated tablets:
                  Floating multi-layer coated tablets were designed based on gas 
formation. The system consists of a drug containing core tablet coated with a protective 
layer (Hydroxy propyl methyl cellulose), a gas forming layer (Sodium bicarbonate) and a 
gas-entrapped membrane, respectively. The acrylic polymers (Eudragit® RL 30D, RS 
30D, NE 30D) and Ethylcellulose were suitable film for the system, and was chosen as a 
gas-entrapped membrane due to its high flexibility and high water permeability. The 
obtained tablets enabled to float due to the carbon-dioxide gas formation and the gas 
entrapment by polymeric membrane.
1.8.3.2 Raft system:
                A gel–forming solution (e.g. Sodium alginate solution containing 
carbonates or bicarbonates) swells and forms a viscous cohesive gel containing entrapped 
Carbon di-oxide bubbles on contact with gastric fluid. Formulations also typically contain 
antacids such as Aluminium hydroxide or Calcium carbonate to reduce gastric acidity. 
Because raft forming produce layer on the top of the gastric fluid, they are often used for 
gastro esophageal reflux treatment such as liquid gaviscon.
1.8.2.1 Magnetic system:
                 This system is based on a simple idea is that the dosage form contains a 
small internal magnet and a magnet placed on the abdomen over the position of stomach.
The internal tablet guided by the oesophagus with an external magnet. These 
system seem to work, the external magnet must be positioned with a degree of precision 
that might compromise patient compliance. 
1.9. Criteria for selection of drug candidate for GRDF6:                 
 Drugs required to exert local therapeutic action in the stomach e.g. 
Misoprostol, 5-Flurouracil, Antacids and Anti-reflux preparations, Anti-
helicobacter pylori agents and certain enzymes.
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 Drugs exhibiting site-specific absorption in the stomach or upper part of the 
small intestine. e.g. Atenolol, Furosemide, Levodopa, p-Aminobenzoic acid, 
Piretanide and Salbutamol.
 Drugs unstable in lower part of GI tract. e.g. Captopril.
 Drugs insoluble in intestinal fluids (Acid soluble basic drugs). e.g. 
Chlordiazepoxide, Chlorpheniramine, Cinnarizine, Dizapam, Diltiazem,    
                  Metoprolol, Propranolol and Verapamil
 Drugs with variable bioavailability. e.g. Sotalol hydrochloride and 
Levodopa.
1.9.1.Advantages of FDDS3,5:                      
 It is advantageous for drugs absorbed through the stomach. for e.g. 
Riboflavin, Ferrous salts and Antacids.
 It is not restricted to medicaments, which are absorbed from stomach, since 
it has been found that these are equally efficacious with medicaments  which 
are absorbed from the intestine.
 It is advantageous for drugs meant for local action in the stomach. for e.g. 
Antacids and Antiulcer drugs.
 The dissolved drug gets available for absorption in the small intestine after 
emptying of the stomach contents. It is therefore expected that a drug will be 
fully absorbed from the floating dosage forms if it remains in the solution 
form even at the alkaline pH of the intestine. 
 It releases drug slowly and for prolonged period of time and hence reduces 
dosing frequency. 
 It reduces fluctuations in circulating blood level of drug as shown by the 
conventional dosage form.
 It shows more uniform levels of drug in plasma.
 As it prolongs drug release it helps to avoid night time dosing. 
 It reduces GIT irritation and other dose related side effects.
 It increases patient compliance as the dosing frequency is reduced.
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1.9.2.Disadvantages of FDDS3
 The requirement of high levels of fluid in stomach for delivery system to float 
and work efficiently.
 These systems require the presence of food to delay their gastric emptying 
time.
 The drugs having solubility or stability problems in the highly acidic gastric 
environment or that are irritants to gastric mucosa are not good candidates for 
floating drug delivery system.
 In case of bioadhesive system which form electrostatic and hydrogen bond 
with mucus, the acidic environment and mucus prevent bond formation at 
mucus polymer interface.
 The dosage form designed to stay in stomach in the fasted state musts be 
capable of resisting the housekeeper waves of phase III of the MMC.     
 The drugs which are well absorbed along the entire Gastro intestinal tract and 
which undergoes significant first pass metabolism, may not be desirable 
candidates for FDDS, since slow gastric emptying lead to reduced systemic 
bioavailability.
       
1.9.3.Marketed preparations of FDDS:6                                                   
Table 2: Marketed preparations of Floating drug delivery systems
S. No. Product Active ingredients
1 Madopar Levodopa and Benserazide
2 Valrelease Diazepam
3 Liquid Gavison Alginic acid and bicarbonate
4 Conviron Ferrous sulphate
5 Cifran OD Ciprofloxacin
6 Cytochek Misoprostol
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REVIEW OF LITERATURE
1.Mona Semalty et al7(2010)  were attempted to Prepare and characterize 
gastroretentive floating microspheres of ofloxacinHcl using polymers ethyl cellulose, 
poly vinyl pyrrolidine  K-90&poly vinyl alcohol  in different ratios by solvent 
diffusion method. In vitro floatability studies revealed that most of the microspheres 
(52.5% to 95.5%) were floatable. The in vitro drug release was found to be in the 
range of 39.64 to 93.64%  at the end of 6 hours.
2.Shankraiah M etal8(2011) were attempted to formulate and evaluate floating 
microspheres of levofloxacin using polymers HPMC and Eudragit S100 in different 
ratios by emulsion solvent evaporation technique. The drug was encapsulated with 
HPMC and Eudragit S 100 in different polymers ratios. The % Yield of microspheres 
was high in HPMC batches over Eudragit S 100 batches.  Percentage Buoyancy of 
microspheres was found to be in the range of 63.38%75.58% indicated that most of 
the microspheres were still floatable after 12hours because of their low density and 
internal voids. Microspheres of levofloxacin with HPMC showed enhanced release 
rate when compared to Levofloxacin with Eudragit S 100.
3.P.Manisha et al9(2010)were attempted to prepare and evalute the                                                                                    
floating Microspheres of famotidine using hydroxylpropyl methylcellulose (HPMC) 
and Ethylcellulose (EC) as the rate controlling polymers by solvent evaporation (Oil-
in-water emulsion) technique. Results showed  that  the  polymer  ratio  and  stirring  
speed  affected  the  size,  incorporation  efficiency  and  drug  release  of 
microspheres (> 12 h), floating time (> 12 hr) and the best results were obtained at the 
ratio of HPMC:EC (1:6).
4.M.Najmuddin et al10(2010)were attempted to Formulate and evalute the floating 
micro spheres of ketoprofen using HPMC and two different grades of ethylcellulose 
as polymer by solvent evaporation method . Formulaion  F5  prepared  with  HPMC 5 
cps  and  ethylcellulose  7‐10  cps  which  exhibited  excellent  micromeritic  
properties, percentage yield, in vitro buoyancy, incorporation efficiency and 
percentage drug release 98.88% for a period of 12 hrs. 
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5.Alkesh T et al11 (2011)formulated floating tablets of Acyclovir using gas 
forming agents like sodium bicarbonate and natural gums like Locust bean gum, 
Sodium alginate and Xanthan gum by effervescent technique.  The results of in 
vitro release studies showed that optimized formulation F7 could sustain drug 
release (99.08%) for 16 hr and remain buoyant for 24 hr. F7 formulation fitted 
best for Korsemeyer –Peppas model and showed no significant change in physical 
appearance, drug content, floatability or in vitro dissolution pattern after storage 
at 45 °C/75% RH for two months.
6.Muthusamy K et al12 (2005) prepared and evaluated Lansoprazole floating 
micropellets. The floating micropellets were prepared by emulsion solvent 
diffusion technique. The prepared micropellets showed sustained release of 
Lansoprazole in gastric medium for more than 12 hours, thereby improving its 
oral bioavailability.
7.ElKamel AH et al13 (2003)developed floating microparticles of Ketoprofen 
using Eudragit S & L as polymers and studied the gastric ulcerogenic effect of 
Ketoprofen floating microparticles with plain Ketoprofen. Ketoprofen loaded 
microparticleswerefound to be less ulcerogenic and they protected the stomach by 
preventing the intimate contact of Ketoprofen with gastric mucosa.
8.El-GibalyI et al14 (2002)formulated and compared chitosan floating 
microcapsules containing Melatonin with conventional non-floating Chitosan 
microspheres. Floating microcapsules showed zero order release kinetics and 
more than 12 hrs floating time in vitro. Moreover, these floating microcapsules 
greatlyretarded the drug release lasting for several hours while it was almost 
instant fromconventional microspheres.
9.Basak SC et al15 (2004)developed oral floating matrix tablet of Ciprofloxacin 
using gas generating agent sodium bicarbonate, and hydrophilic polymer 
Hydroxypropyl methyl cellulose. Drug release study of these tablets indicated 
38
controlled sustained release of Ciprofloxacin, thereby improving its 
bioavailability. 
10.Bhaskaran S et al(2004)developed hydrodynamic oral floating controlled 
delivery of Diltiazem hydrochloride as sustained release macropellets. Results 
revealed that the system had excellent floating ability and sustained release 
characteristics of zero order kinetics. 
11.Baumgartner S etal16(2000) developed floating matrix tablets containing 
Hydroxypropyl Methyl Cellulose, which after oral administration were designed 
to prolong the gastric residence time, increase bioavailability and diminish the 
side effects of irritating drugs. The importance of the composition optimization, 
formulation aspects and characterization of tablets were examined. The 
investigation showed that the tablet composition and mechanical strength have 
great influence on the floating and drug release properties of the tablets. They 
concluded that drug release from the tablets followed non-Fickian transport. 
12.Joseph NJ et al17 (2002)studied the effect of solvent evaporation technique on 
floating type hollow polycarbonate microsphere of Piroxicam which were capable 
of floating on simulated gastric fluid. Pharmacokinetic analysis showed that the 
bioavailability of Piroxicam hollow microsphere was about 1.4 times that of free 
drug and was about 4.3 times for the dosage form consisting of microsphere plus 
the loading dose. The elimination half life was increased by three times that of 
free drug.
13.Chandira M et al  (2009) prepared floating tablets of Diltiazem 
Hydrochloride using direct compression technique using Hydrophilic polymer 
like HPMC K4M,HPMC K15M and hydrophobic polymer like Ethylcellulose as 
matrix materials in various quantities (%w/w), sodium bicarbonate, citric acid, 
magnesium stearate, talc and lactose in varying ratio to formulate the floating 
tablets. They observed that tablets of batch F6 followed the results obtained, it 
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was concluded that the formulation F6 is the best formulations as the extent of 
drug release was found to be around 99.81 % at the desired time 12 hrs.
14.Chandira M et al (2009)formulated floating tablets of famotidine using 
directly compression technique with polymers like HPMC K4M and 
HPMCK100M for theirgel-forming properties. They reported that gas powered 
gastroretentivefloatingTablets of famotidine containing 40mg HPMCK100M and 
Xanthan gum provides a better option for controlled release action and improved 
bioavailability.
15.Ozdemir N et al (2000)developed floating bilayer tablet of 
Furosemidecyclodextrin inclusion complex. They determined the gastric 
residence time using radiographs by adding BaSO4 and reported that the tablet 
stayed in stomach for 6 hours. Also the bioavailability of Furosemide from 
floating tablet was about 1.8 times those of the conventional tablet and also 
significant in vitro – in vivo correlation was detected.
16.Gohel MC et al18 (2004) developed a more relevant in vitro dissolution 
method to evaluate Carbamazepine floating drug delivery system. The test 
showed good in vitro– in vivo correlation since the gastric volume, gastric 
emptying and gastric acid secretion rate were mimicked. 
17.Kawashima Y et al19 (1992)  reported the formulation of hollow microspheres 
that floats in stomach. The hollow microspheres (microballons) loaded with either 
Tranilast or Ibuprofen in an outer enteric acrylic polymer (Eudragit S) shell and 
prepared by a novel emulsion-solvent diffusion method were studied for their 
physico-chemical properties, such as particle diameter, particle density and 
crystalline form of the drug. The microballoons floated continuously over the 
surface of acidic dissolution medium containing surfactant for 12 hours in vitro.
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18.Shoufeng L et al (2001)developed an optimized gastric floating drug delivery 
system        for oral controlled delivery of Calcium. A central, composite Box-
Wilson design for the controlled release of calcium was used with three 
formulation variables; HPMC loading, citric acid loadingand magnesium stearate 
loading. All three formulation variables were found to significantly affect release 
properties. Only HPMC loading was found to be significant for floating 
properties. 
19.Roughe N et al (1998) conducted a study to evaluate the factors that improves 
the in vitro buoyancy and drug release profile of floating minitablets containing 
either Piretinide or Atenolol as the model drug. The buoyancy of the minitablets 
was achieved either by the swelling of the excipients or by incorporating gas 
generating agent, sodium bicarbonate. The study concluded that it is possible to 
produce minitablets containing either Piretinide or Atenolol, which have a 
positive resultant weight during more than 6 hr and satisfactory release profiles.
20.Nath BS et al (1995) reported the development of wax and fat embedded 
microspheres of Ibuprofen as a drug delivery system. Paraffin, cetyl alcohol and 
stearic acid microspheres were prepared using methylcellulose, sodium alginate, 
and polysorbate 80 as emulsifying agents. Drug release was erosion controlled. 
The type of emulgent used influenced release kinetics. Retardation of drug release 
followed the order of stearic acid – methylcellulose, cetyl alcohol, polysorbate 80, 
and paraffinsodium alginate. Drug content was found to be uniform in all systems. 
21.Maru AD et al20 (1987)prepared intragastric floating controlled release tablets 
of Nitroglycerine and cimetidine.  In vitro floating characteristics of 
nitroglycerine showed that the tablets continued to float on the surface of water 
for more than 24 hours which is the maximum duration during which the tablet is 
expected to release its total quantity of drug. Buoyancy of the formulation in vivo 
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was confirmed through endoscopy after administration of cimetidine floating 
tablets to the patients suffering from peptic ulcer. 
22.Sangekar S et al21 (1987)studied the effect of food and specific gravity on the 
gastric retention of floating and non-floating tablet formulations. The results 
obtained indicated that the presence of food in stomach appeared to prolong 
gastric retention significantly of both floating and non-floating tablet. 
23.Hilton AK et al22(1992)fabricated oral sustained release floating tablets of 
Amoxycillintrihydrate and carried out in vitro – in vivo evaluation. From the 
studies, it showed that the drug slowly released in the stomach by diffusion from 
the floating matrix tablet and then trickled towards the proximal intestine where 
absorption occurs. It improved the delivery of antibiotic resulting in more uniform 
levels of antibiotic following less frequent oral dosing. 
24.Menon A et al23 (1994) reported the formulation of a monolithic floating 
dosage form for Furosemide using factorial design keeping the drug to polymer 
ratio, polymer to polymer ratio and polymer grade as the three factors. The 
optimized formulation thus obtained was found to have a good in vitro / in vivo 
correlation. 
25.Kohri N et al24 (1996) revealed that gastric retained tablet of Sulpiride 
prepared from Carbopol 934P showed sustained release characteristics which was 
suitable forimproving and extending the oral bioavailability of Sulpiride. 
26.Deshpande AA et al25 (1997)developed novel controlled release gastric 
retention system, which consists of a matrix tablet, coated with a permeable 
membrane. Tablets containing soluble drug Chlorpheniramine maleate and poorly 
soluble drug Riboflavin were compressed. Studies showed that, the chances of 
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elimination through the pylorus greatly reduced due to tablets expansion and the 
tablet expelled out of stomach at the end of the drug release.
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AIM AND OBJECTIVES
 To Formulate GRTS for Ziprasidone Hydrochloride using the Microballons 
approach.
 Microballons are drug entrapped hollow Microspheres which will float on the 
gastric content by virtue of having low density.
 The aim is to prepare microballons using two different polymeric systems viz:
1.Ethyl Cellulose 
2.Hydroxy Propyl Methyl Cellulose
 The Microballons shall be characterized and in vitro dissolution profile shall be 
evaluated.
 The aim of the present work is to formulate Floating Microcapsules for prolonged 
delivery of Ziprasidone Hydrochloride using Ethyl cellulose as release retarding 
polymer, and Hydroxy Propyl Methyl Cellulose as pore former.
 The formulation optimization was done using full factorial 2 3 design of 
experiments matrix.
 In-vitro dissolution study on the  formulations was performed in 0.1N HCL
medium.
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PLAN OF WORK
 Step: 1 Preformulation Study
 API Characterization
o Physical Appearance
o Solubility studies
 Drug-Excipient Compatibilty Studies
o Physical Compatibility
o FT-IR Spectrophotometry
 Analytical Method Development
 Step: 2 Selection of the method(Solvent Evaporation Technique)
 Step: 3 Design of experiments by 23 full factorial design
 Step: 4 Optimization through results of evaluation
 Step:5 In-vitro dissolution testing
 Step:6 Data interpretation and reporting the results
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DRUG PROFILE26
ZIPRASIDONE HYDROCHLORIDE
Chemical name :  5-[2-[4-(1,2-Benzisothiazol-3-yl)-1 -piperazinyl]ethyl]-6-  
                                                   chloro-1,3-dihydro-2H  indol- 2-one hydrochloride
Empirical formula :  C21H21ClN4OS.HCL
Molecular weight : 449.4
Structure : 
                                                        
                        
Physicochemical Profile
Description:
              white to off-white crystalline powder
                                              
Solubility:
              Soluble to 10 mm in DMSO
PHARMACEUTICAL PROFILE
Dosage Forms and dose:
Capsules: 20 mg, 40 mg, 60 mg, 80 mg
             I.M Injection: 20 mg/ml
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Pharmacopoeial status:
           United States Pharmacopoeia
Storage:
              It should be stored in an airtight container and protected from   light 
ANALYTICAL PROFILE
Spectrophotometry:
    Spectrophotometric determination of Ziprasidone Hydrochloridein 0.1 HCL 
with the the λmax at 318nm has been reported.
                                     
PHARMACOKINETIC PROFILE
Oral absorption:
                       60%
Plasma half life:
                      7 hours.
Protein Binding:
         99 % ( Plasma proteins) 
PHARMACOLOGICAL PROFILE
Therapeutical category:
                      Antipsychotic
Mechanism of action :
                       Ziprasidone's antipsychotic activity is likely due to a combination of its 
antagonistic function at D2 receptors in the mesolimbic pathways and at 5HT2A 
receptors in the frontal cortex. Alleviation of positive symptoms is due to antagonism at 
D2 receptors while relief of negative symptoms are due to 5HT2A antagonism.
THERAPEUTIC/CLINICAL USES:
                        Ziprasidone Hydrochloride is indicated for the treatment of schizophrenia 
and related psychotic disorders.
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ADVERSE EFFECTS      
CNS:
       Dizziness, Drowsiness, Dystonia, Hypertonia, Asthenia, Akathisia, Extrapyramidal 
reactions, Agitation, Headache, Insomnia, Personality disorder, Paresthesia, Speech 
disorder, Neuroleptic malignant syndrome, Seizures and Suicide attempt.
CV:
     Orthostatic hypotension, Hypertension, Tachycardia, Arrhythmias (from prolonged 
QT interval)
EENT:
       Abnormal vision and  Rhinitis
GI:
     Nausea, Vomiting, Diarrhea, Constipation, Dyspepsia, Dry mouth and Anorexia
MUSCULOSKELETAL:
       Myalgia
RESPIRATORY:
         Cough and Cold symptoms
SKIN:
         Urticaria,Rrash, Fungal dermatitis, Diaphoresis and Photosensitivity
OTHER:
          Accidental injury, Pain at I.M. injection site
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POLYMER PROFILE
1.HYDROXY PROPYL METHYL CELLULOSE27
Synonyms:
           Hydroxy Propyl Methyl Cellulose; HPMC; Methocel; Benecel MHPC; Methyl 
hydroxy propyl cellulose; Methylcellulose propylene glycol ether; Metolose.
Chemical name: 
           Cellulose hydroxy propyl methyl ether
Functional category:
            Coating agent, Film-former, Rate-controlling polymer for sustained release, 
stabilizing agent, Suspending agent, Tablet binder, Viscosity-increasing agent.
Physicochemical Properties
Description:
            White to slightly off white powder, free flowing powder
Methoxyl content: 
           19-24%
Hydroxypropyl content:
          7-12%
Bulk density: 
           0.12 – 0.15 g/ml
pH (1% content): 
           5.5-8
Solubility:
           HPMC K4M is a medium viscosity polymer which is soluble in water
Viscosity:
             4000(mpas)
Applications:
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 Hypromellose is widely used in oral, ophthalmic and Topical pharmaceutical 
formulations.In oral products; Hypromellose is primarily used as a tablet binder, 
in film coating, and as a matrix for use in extended-release tablet formulations.
 Concentrations between 2% and 5% w/w may be used as a binder in either wet- or 
dry-granulation process. High-viscosity grades may be used to retard the release 
of drugs from a matrix at levels of 10-80% w/w in Tablets and Capsules.
 Depending upon the viscosity grade, concentrations of 2-20% w/w are used for 
film-forming solutions to film-coat tablets. Lower viscosity grades are used in 
aqueous film coating solutions, while higher-viscosity grades are used with 
organic solvents. 
 Hypromellose is also used as suspending agent in topical formulations. 
Hypromellose at concentrations between 0.45-1.0% w/w may be added as 
thickening agent to vehicles for Eye drops and Artificial tear solutions.
 Hypromellose is also used as an Emulsifier, Suspending agent, and Stabilizing 
agent in topical gels and Ointments..
 Hypromellose is used in the manufacture of capsules, as an adhesive in plastic 
bandages, and as a wetting agent for hard contact lenses. It is also widely used in 
cosmetics and Food products.
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2.ETHYL CELLULOSE
                 Ethyl cellulose is a chain of β-anhydro glucose units joined together by acetal 
linkage.
                 It is prepared from wood.pulp or chemical cotton by treatment with alkali 
and ethylation of the alkali cellulose with Ethyl chloride. Commercial Ethyl Cellulose 
has an ethoxy content of 43-50 %. A 47 % product softens at 140oC and is soluble in 
Ethyl Acetate, Benzene, Toluene, Xylem and Butanol. The properties and 
pharmaceutical applications of Ethyl cellulose are as follows:
Synonyms:
               Ethocel
Description:
               A tasteless, odourless, free flowing, white to light tan powder.
Specific gravity:
              1.14
Softening temperature:
               152-162 0 C
Emperical formula and Molecular weight: 
               Ethyl cellulose with complete Ethoxyl substitution (DS = 3) is C12H23O6 
(C12H22O5)nC12H23O5  where n can vary to provide a wide variety of molecular weights. 
Ethylcellulose, an ethyl ether of cellulose, is a long-chain polymer of β-anhydroglucose 
units joined together by Acetal linkages.
Functional Category:  
               Coating agent, Tablet binder, Tablet filler and Viscosity-increasing agent.                             
Solubility:
            Insoluble in water, glycerin, propylene glycol, but soluble in varying degrees in 
organic solvents.
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Viscosity: 
             A property of ethyl cellulose such as tensile strength, elongation and flexibility 
depends largely upon the degree of polymerization, which can be measured by 
viscosity. Therefore, within each type-based Ethoxyl content there exists low to 
high viscosity types, based on degree of polymerization
Stability:
            It is resistant to alkali both dilute and concentrated but more sensitive to acidic 
materials than cellulosic ethers.
Applications 
1. Binder in tablets:
       Ethyl cellulose may be dry blended and wet granulated with a solvent such
as alcohol. Tablets made with Ethyl cellulose as binder tend to exhibit poor 
dissolution and poor drug absorption.
2. Coating material for tablets:
      Ethyl cellulose by itself forms a water insoluble film coating. It is 
commonly used with Hydroxy Propyl Methyl Cellulose to alter the solubility of 
the film. Other materials may be used for this as well.
3.  Coating material for stabilization:
         Ethyl cellulose dissolved in Iso p rop ano l  i s  u sed  to  co a t  pa r t i c l es  o f  
d ru gs  t o  fo rm Microcapsules. This type of Microcapsules slows dissolution of 
the drug as a function of Microcapsule wall thickness.
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3.TWEEN-80
1. Nonproprietary Names:
        BP: Polysorbate 80
        JP: Polysorbate 80
        PhEur:  Polysorbate 80
        USP-NF: Polysorbate 80
2. Synonyms:
              Polysorbate 80 Atlas E; Armotan PMO 20; Capmul POE-O; Cremophor PS 80; 
Crillet 4; Crillet 50; Drewmulse POE-SMO; Drewpone 80K; Durfax 80;Durfax 80K; 
E433; Emrite 6120; Eumulgin SMO; Glycosperse O-20; Hodag PSMO-20; Liposorb O-
20; Liposorb O-20K; Montanox80; polyoxyethylene 20 oleate; polysorbatum 80; 
Protasorb O-20; Ritabate 80; (Z)-sorbitan mono-9-octadecenoate poly(oxy1,2-ethanediyl) 
derivatives; Tego SMO 80; Tego SMO 80V; Tween 80.
3. Chemical Names and CAS Registry Numbers: 
               Polysorbate 80 Polyoxyethylene 20 sorbitanmonooleate (9005-65-6)
4 .Empirical Formula and Molecular Weight:
              C64H124O26,  Mol. wt: 1310
5. Functional Category
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             Dispersing agent; Emulsifying agent; Nonionic surfactant; Solubilizingagent; 
Suspending agent and Wetting agent.
6. structure:
7. Description:
                    Polysorbates have a characteristic odor and a warm, somewhat bitter taste. 
Their colors and physical forms at 2580c , although it should be noted that the absolute 
color intensity of the products may vary from batch to batch and from manufacturer to 
manufacturer.
8. Incompatibilities:
                    Discoloration and/or precipitation occur with various substances,especially 
phenols, tannins, tars, and tarlike materials. The antimicrobial activity of Paraben 
preservatives is reduced in the presence of Polysorbates.
9. Stability and Storage Conditions:
                   Polysorbates are stable to electrolytes and weak acids and bases;gradual 
saponification occurs with strong acids and bases. The oleicacid esters are sensitive to 
oxidation. Polysorbates are hygroscopic and should be examined for water content prior 
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to use and dried if necessary. Also, in common with other polyoxyethylene 
surfactants,prolonged storage can lead to the formation of peroxides. Polysorbates should 
be stored in a well-closed container, protected from light, in a cool and dry place.
10.Applications in Pharmaceutical Formulation:
                  Polysorbates containing 20 units of Oxyethylene are hydrophilic nonionic 
surfactants that are used widely as Emulsifying agents inthe preparation of stable oil-in-
water pharmaceutical emulsions. They may also be used as Solubilizing agents for a 
variety of substances including essential oils and oil-soluble vitamins, and as wetting 
agents in the formulation of oral and parenteral suspensions.They have been found to be 
useful in improving the oral bioavailability of drug molecules that are substrates for P-
glycoprotein.
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4.ISOPROPYL ALCOHOL
Chemical Name:  
        Isopropyl alcohol
Formula: 
        C3H8O
Synonym:  
         Propan-2-ol, 2-propanol or the abbreviation 
Physical and chemical properties
Molecular weight:
        60.01 g/mole
Color:
       Colorless 
Nature :
       Liquid
Odour :
      Pleasant
Taste :
      Slight bitter
Density:
      0.786 g/cm3  
Boiling Point:
      82.5o C
Solubility:
            Easily soluble in Cold water, Hot water, Methanol, Diethyl ether, n-octanol, 
Acetone.Insoluble in salt solution.Soluble in benzene.Miscible with most organic 
solvents including Alcohol, Ethyl alcohol and Chloroform.
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Melting point:
           89C (with decomposition)
Functional category:
Granulating agent 
Applications:
 It is used dissolves a wide range of Non –polar compounds. It also evaporates 
quickly and is relatively Non-toxic, compared to alternative solvents.
 It is used widely as a solvent and as a cleaning fluid, especially for dissolving 
Lipophilic contaminants such as oils.
 As a biological specimen preservative, Isopropyl alcohol provides a 
comparatively non-toxic alternative to Formaldehyde and other synthetic 
preservatives. Isopropyl alcohol solutions of 90-99% are optimal for preserving 
specimens, although concentrations as low as 70% can be used in emergencies.
 Disinfecting pads typically contain a 60–70% solution of Isopropyl alcohol in 
water. Isopropyl alcohol is also commonly used as cleaner and solvent in industry.
 Isopropyl alcohol is often used in DNA extraction. It is added to a DNA solution 
in order to precipitate the DNA into a 'pellet' after centrifuging the DNA. This is 
possible because DNA is insoluble in Isopropyl alcohol
Stability and Storage:
              Store in a segregated and approved area. Keep container in a cool, well-
ventilated area. Keep container tightly closed and sealed until ready for use. Avoid all 
possible sources of ignition spark or flame.
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MATERIALS AND METHODS
                  The chemicals and reagents used in the study are given in Table 3 and the 
equipments used are listed in Table 4
Table 3: List of Materials and their Suppliers
S.
No.
Name of Materials Supplier
1 Ziprasidone Hydrochloride Marko Labs,Mumbai
2 Ethyl Cellulose Marko Labs,Mumbai
3 Hydroxy Propyl Methyl Cellulose Marko Labs,Mumbai
4 Dichloromethane Marko Labs,Mumbai
5 Isopropyl alcohol S.D fine Chemicals,Mumbai
6 Tween-80 S.D fine Chemicals,Mumbai
             
Table 4: List of Equipments
S.NO Equipments Company
1 Glassware Borosil,Chennai
2 Stirrer Remi stirrer2500rpm-Delhi
3 Hot plate Optics technology-Delhi
4 Tray dryer Optics technology-Delhi
5 Sonicator PCI-SS-Delhi
6 Optical microscope Dalal &co-Chennai
7 UV Spectrophotometer E2371 spectrophotometer-Mumbai
8 Dissolution apparatus Campbell electronics-Mumbai
9 Scanning electron microscope Hitachi model SU 1500,JEOL 
JSM T330A scanning microscope-
Japan
10 FTIR 200 spectrometer Spectrum one Perkin Elmar-USA
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METHODS
Preformulation Studies28:
              Preformulation testing is the first step in the rationale development of dosage 
forms of a drug substance. It can be defined as an investigation of Physico-chemical 
properties of a new drug substance alone and when combined with the excipients, to 
generate data useful to the formulator in developing safe, potent, bio-available and 
efficacious dosage form, which can be mass produced. The goals of preformulation 
studies are,
 To establish the physicochemical parameter of new drug substances.
 To establish the kinetic rate profile.
 To establish physical characteristics.
 To establish compatibility with the common excipients.
Hence, the following parameters were selected for the preformulation studies of the pure 
drug.
Identification of pure drug:
            Identification of Ziprasidone Hydrochloride was examined by FT-IR and was 
compared with the spectrum of Ziprasidone Hydrochloride.
Solubility Analysis:
             Solubility analysis was done to select suitable solvents/solvents to dissolve the 
drug, Polymer as well as various excipients used for the formulation of microspheres.
Melting point determination:
            Melting point of Ziprasidone was determined by using Melting point apparatus 
(Capillary tube).melting point of a drug sample is a first indication of purity of the 
sample. The presence of relatively small amount of impurity can be detected by lowering 
as well as widening in the melting point range.
Compatibility studies:
                Compatibility of the Ziprasidone Hydrochloride with Ethyl cellulose and 
Hydroxy Propyl Methyl Cellulose used to formulate Microballons was established by FT-
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IR. Spectral analysis of Ziprasidone, Ethyl Cellulose and Hydroxy Propyl Methyl 
Cellulose and combination of the Ziprasidone with Polymer was carried out to investigate 
any changes in chemical composition of the drug after combining it with the excipients.
Determination of λmax:.
                 100 mg of Ziprasidone was dissolved in Methanol and diluted to 100ml with 
the 0.1N HCL 1ml of this solution was diluted to 10 ml with 0.1N HCL  this gives the 
solution of concentration 100 mcg/ml. from this 1ml solution was transferred in to 10ml 
volumetric flask and diluted with 0.1N HCL this  gives the solution of concentration 10 
mcg/ml and this solution was examined between 278 nm. The maximum obtained in the 
graph was considered as λmax. The solution has shown an absorption maximum at 
278nm.
STANDARD CALIBRATION CURVE FOR ZIPRASIDONE HYDROCHLORIDE
In simulated gastric fluid (Acidic buffer) pH 1.2
                      Weighed quantity of Ziprasidone Hydrochloride (100mg) was dissolved in 
pH1.2 buffer and the volume was made up to 100ml with the same medium. From this 
stock solution, serial dilutions were made to obtain the solutions in concentration ranging 
from 5-60µg/ml. The absorbance was measured at 300nm.
FORMULATION OF MICROBALLONS29,30,31,32,33:
Trial and error method: (Preliminary experiments) 
                                  Previously many trials were run for the preparation of Floating 
Microcapsules of Ziprasidone Hydrochloride by Solvent Evaporation Technique. Trials 
were made by changing the temperature and stirring speed, concentration of the Ethyl 
Cellulose,Hydroxy propyl methyl cellulose and Ziprasidone concentration. After so many 
trials, it was concluded that temperature plays a very critical role in the formation of 
Floating Microcapsules, it is a continuous process of stirring, with the combination of 
Hydrophilic Non –ionic surfactant and Ethyl cellulose  as Release retarding polymer, 
and Hydroxy Propyl Methyl Cellulose as pore former. Every step in the process was 
optimized by performing experiments through trial and error method.
Preparation of Floating Microspheres: 
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                        Ziprasidone Hydrochloride Floating Microspheres were prepared by the 
Solvent Evaporation Technique. The following steps were followed for the preparation of 
the Floating Microcapsules
 Ziprasidone, Ethyl cellulose and Hydroxy Propyl Methyl Cellulose were 
dissolved in solvent mixture of 15 ml of Isopropyl alcohol and 15 ml of 
Dichloromethane.
 The solution was filled into a syringe fitted with 22 Gauge needle.
 It was dropped at a rate of 50 drops/minute into a beaker containing 500 ml water 
with 2.5 ml Tween-80 as the continuous phase.
 The continuous phase was stirred using 3 blade Remi stirrer at 500 rpm.
 After complete addition of the Drug-polymer solution, the mixture was allowed to 
stir for 2 hours.
 The Microcapsules Floating on the top of the continuous phase were collected and 
dried at 400C for 1 hour in a hot air oven. The Floating Microcapsules were 
Stored in an air tight containers till taken for further evaluation.
 The dried Microcapsules were weighed and the yield was determined.
          DOE34: 
 A full 2 3  factorial design14-15 was introduced to optimize the 
formulation of Ziprasidone loaded EC+ HPMC Microballons using the 
Solvent Evaporation Technique 
 Entrapment Efficiency was considered as a measurable parameter for this 
study.
 A design matrix comprising of 8 experimental runs was constructed using 
DOE Pro XL Software to investigate the effect of three factors.
                    Ziprasidone concentration as (A), 
                    EC concentration as (B) and
                    HPMC concentration as (C).
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 on the response variable i.e. % Drug released at 1 hour (D1) and 
percentage of Drug release at 8 hours (D8) were considered as measurable 
parameters.
 Volume of solvent (50 ml), ratio  of IPA and DCM (1:1), volume of 
aqueous phase (500 ml)  concentration of Tween (2.5ml), stirring speed 
(500 rpm) and temperature  (ambient) were kept constant.
Table 5:Full factorial DOE Floating Microcapsules of Ziprasidone Hydrochloride
L-low,         H-high ;
Table 6:DOE (mg/unit)
S.NO Ingredients LLL LLH LHL LHH HLL HLH HHL HHH 
F1 F2 F3 F4 F5 F6 F7 F8 
   1 ZIPRASIDONE 100 100 100 100 500 500 500 500
2 EC 7cps 200 200 500 500 200 200 500 500
3 HPMC 6cps 200 500 200 500 200 500 200 500
ZIPRASIDONE- L-100mg, H-500mg,
EC-        L-200mg, H- 500mg,
HPMC- L- 200mg, H- 500mg.
Formulation Ziprasidone Ethyl cellulose Hydroxy propyl 
methyl cellulose
F1 L L L
F2 L L H
F3 L H L
F4 L H H
F5 H L L
F6 H L H
F7 H H L
F8 H H H
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PHOTOGRAPHS OF THE FORMULATIONS OF HIGH ENTRAPMENT 
EFFICIENCY
FIG 15:F3LHL
FIG15.3: F8: HHH
FIG 15.2:F5: HLL
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FIG 15.1:F4: LHH
FIG 15.4:F7: HHL
FIG 15.5: F optima
CHARACTERIZATION OF THE ZIPRASIDONE HYDROCHLORIDE 
FLOATING MICROCAPSULES
Particle size35:
                 Determination of average particle size of Ziprasidone Hydrochloride Floating 
Microcapsules was carried out by Optical Microscopy in which stage micrometer was 
64
employed. A minute quantity of Microcapsules was suspended in Liquid paraffin and 
spread on a clean glass slide and average size of 100 Microcapsules was determined in 
each batch.
Surface Morphology34:
                  Scanning Electron Microscopy has been used to determine Particle 
distribution, Surface topography, Texture and to examine the Morphology of fractured or 
Sectioned surface.SEM studies were carried out by using JEOL JSMT-330A Scanning 
Microscope (Japan).The samples of SEM were prepared by lightly sprinkling the 
Microcapsules powder on a double adhesive tape, which was stuck on an Aluminum stub. 
The stubs were then coated with gold to thickness of about 300A using a Sputter coater. 
The photomicrographs were taken with the help of SEM analyzer.
Drug Entrapment Efficiency35:
                   The Microcapsules sample was powdered using Mortar and Pestle. An 
accurately weighed sample of 20mg of Microspheres was dispersed in 47.5 ml of 0.1N
HCL and 2.5ml of Methanol, and sonicated for 30 minutes at a temperature of 
37.50C.The resultant solution was filtered, and the filtrate was suitably diluted with 0.1N 
HCL .Absorbance was measured at 278nm by using UV Spectroscopy.
                  %Entrapment efficiency = Estimated drug content    x 100
                                                            Theoretical drug content 
The entrapment efficiency values were determined in triplicate.
Estimation of Drug Content:
                     Drug content in the Microcapsules was calculated by UV
Spectrophotometric method. A sample of Microcapsules equivalent to 100 mg was
dissolved in 25 ml Methanol and the volume was adjusted upto 100 ml using 0.1N HCL. 
The solution was filtered through Whatman Filter Paper. Then the filtrate was assayed for 
drug content by measuring the absorbance at 278 nm after suitable dilution.
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Percentage Yield:
                     The percentage yield of the prepared microspheres was determined by using 
the formula.
                 Percentage yield  = Practical yield   x   100   
                                                   Theoretical yield
In-vitro dissolution36,37,38,39: 
                       Dissolution is the main evaluation study conducted for the estimation of 
the drug release from the dosage form. USP-TYPE II apparatus was selected for the 
study. Formulations with Entrapment Efficiency more than 65% were selected for the 
study. The Microcapsules equivalent to 100mg of drug were weighed accurately and 
filled in the capsule shells. Dissolution profiles were carried out in the following media:
(1) 0.1N HCL for 2 hours
The parameters for dissolution apparatus for all the above runs were kept constant as 
described below:
Type of apparatus:
                     USP II.
RPM:
                    50
Temperature:
                      N=8 samples
                     37.50±0.50C
Preparation of Buffer Solutions:
1. Preparation of pH 1.2 Buffer: place 8.5 ml of Hydrochloric acid in 1000 ml of 
Distilled water.
METHOD FOR DISSOLUTION:
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                        A total of 8 formulations were selected for the dissolution with Drug 
Entrapment more than 65%. These formulations were taken as n=8 for the dissolution. 
The method dissolution is as follows.
             In vitro dissolution testing was conducted on Microcapsules equivalent to 100 mg 
of Ziprasidone.
 Microcapsules were filled in hard gelatin capsules shells
 USP Type I apparatus was used
 Media 900 ml 0.1N HCL
 RPM: 50 rpm
 Time points: 0. 0.5, 1, 2, 4 and 8 hours
 Estimation by UV spectrophotometry.
 The dissolution vessels must be filled with the respective dissolution 
media. The dissolution parameters such as temperature, stirring speed 
must be set before starting of the dissolution.
 As the dissolution assembly reaches the temperature, sometime must be 
allowed for the paddles to rotate, after which the sample should be 
dropped carefully and the time must be noted.
 At the prescribed time intervals, aliquots(5ml) must be withdrawn with 
sampling tubes, at the same time equal quantity(5ml) of dissolution 
medium must replaced to maintain the volume of the medium.
 Withdrawn aliquots must be suitably diluted with the dissolution medium, 
and analyzed spectrophotometrically.
 Drug release was calculated and tabulated.
MECHANISM OF DRUG RELEASE40
                    To analyze the mechanism of the drug release rate kinetics of the dosage 
form, the data obtained were plotted as
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i. Cumulative percentage drug released Vs Time (In-vitro drug release plots)
ii. Cumulative percentage drug released Vs Square root of time (Higuchi’s plots)
iii. Log cumulative percentage drug remaining Vs Time (First order plots)
iv. Log percentage drug released Vs Log time (Peppas plots)
Higuchi release model:
                   To study the Higuchi release kinetics, the release rate data was fitted to the 
following equation. 
                                   F = KH.t ½
Where, ‘F’ is the amount of drug release, 
             ‘KH’ is the release rate constant, and 
              ‘t’ is the release time
                                  When the data is plotted as a cumulative percentage drug release 
versus square root of time, yields a straight line, indicating that the drug was released by 
diffusion mechanism. The slope is equal to ‘K’.
Korsmeyer and Peppas release model:
                    The release rate data were fitted to the following equation,
                                   Mt / M∞   = KM. tn
Where, Mt / M∞ is the fraction of drug release,
                  ‘KM’ is the release constant, ‘t’ is the release time,‘n’ is the diffusional 
exponent for the drug release that dependent on the shape of the matrix dosage form. 
When the data is plotted as log percentage release versus log time, yields as straight line 
with a slope equal to ‘n’ and the ‘K’ can be obtained from Y – intercept. For Non-
Fickian release the ‘n’ values falls between 0.5 and 1.0 while for Fickian (case I) 
diffusion n= 0.5 and Zero order release ( case-II transport)
n= 1.0.
Zero order release rate kinetics:
                        To study the zero-order release kinetics the release rate date are fitted to 
the following equation.
                                     F = K0t
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Where ‘F’ is the fraction of drug release, 
            ‘K0’ is the release rate constant and 
             ‘t’ is the release time.
                           When the data is plotted as cumulative percentage drug release versus 
time, if the plot is linear then the date obeys Zero-order release kinetics, with a slope 
equal to K0. 
First order model:
                   This model has also been used to describe absorption and/or elimination of 
some drugs, The release of the drug which followed first order kinetics can be expressed 
by the equation:
                              log C = log C0 -Kt / 2.303
Where, C0 is the initial concentration of drug,
             k is the first order rate constant, and
             t is the time .
The data obtained are plotted as log cumulative percentage of drug remaining vs. time 
which would yield a straight line with a slope of -K/2.303.
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RESULTS AND DISCUSSIONS    A total of eight formulations of Ziprasidone Hydrochloride Floating 
Microcapsules were formulated by Solvent Evaporation Technique using Design Of 
Experiment approach. The formulations were subjected to evaluation parameters like 
Particle size, Surface morphology, Drug entrapment efficiency and In-vitro drug release 
studies.
PREFORMULATION STUDIES
Identification of Pure Drug
FT-IR Spectroscopy:
                  The FT-IR spectrum of the pure drug was found to be similar to the 
standard Microcapsules were shown in the Figures 16 and 17 respectively.
Melting Point Determination:
                   The melting point of the obtained drug sample was found to be 2560C 
which is the reported range of 2550C -2570C.It complies with the USP standards thus 
indicating the purity of the drug soluble.
Solubility Analysis:
                  Ziprasidone Hydrochloride sample was found to be insoluble in water,2-
propanol and Ethanol, sparingly soluble in Acetone. Soluble in 0.1N Sodium 
hydroxide .Solubility analysis is important because the drug has to dissolve in the 
solvents also in the dissolution medium used.
Compatibility studies:
                  From the FT-IR spectra of the pure drug and the combination spectra of 
drug with the polymers, it was observed that all the characteristics peaks of 
Ziprasidone Hydrochloride were present in the combination spectra thus indicating 
the compatibility of the drug with the polymer used.
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FIG 16:  FT-IR OF ZIPRASIDONE HYDROCHLORIDE
        FIG 17: FT-IR OF OPTIMIZED FORMULATION
The FTIR spectrum for the drug loaded Microspheres indicates that there is no          
chemical interaction between the drug and the polymers used during the process of 
Microencapsulation.
STANDARD CALIBRATION CURVE OF ZIPRASIDONE HYDROCHLORIDE 
IN BUFFERS (PH 1.2):
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                  Standard calibrated values of  Ziprasidone Hydrochloride in 0.1N HCL were 
tabulated as follows. They were at different concentrations ranging from 1-5µg/ml in 
acidic buffer (pH 1.2). The curves of respective values are also presented below.
Table 7: CALIBRATION VALUES OF ZIPRASIDONE HYDROCHLORIDE
                           IN 0.1N HCL
S.NO CONCENTRATION ABSORBANCE
1 1 0.107
2 2 0.219
3 3 0.332
4 4 0.441
5 5 0.542
Figure 18:Calibration curve of Ziprasidone Hydrochloride
Percentage yield:
                  Percentage yield of different formulations,F1-F8,were calculated and the yield 
was found to be above 45%.The results are tabulated in the Table 8.The results indicate 
that the Solvent Evaporation  Technique gives excellent yield of the Floating 
Microcapsules.
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Table 8: PERCENTAGE YIELD OF FORMULATION
Formulation Percentage Yield(%w/w)
F1 54.82
F2 59.45
F3 77.92
F4 80.23
F5 46.87
F6 48.57
F7 65.97
F8 68.97
DISCUSSION:
              The yield of microcapsules seems to depend on the concentration of polymer in 
the preparation. For formulation F3 , F4, F7 and F8, where the Ethyl cellulose 
concentration is     500mg, the yields are > 60%.
For formulations with low Ethyl cellulose concetration, the yileds are in the range of 45 
to 55%.
CHARACTERIZATION OF MICROBALLONS
Particle size analysis:
                   Particle size distribution of Microballons was determined by Optical 
Microscope fitted with an Ocular Micrometer and Stage Micrometer.The particle sizes of 
the Microcapsules were found in the range of(65-525µm) for 8formulations(DOE).The 
particle size of the formulations were shown in the table.
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Table9: MEAN PARTICLE SIZE OF THE MICROCAPSULES
OF THE FORMULATIONS.
Figure 19:Mean Particle Size of the Microcapsules using Optical Microscopy
DISCUSSION:
                       For all formulations, the Microspheres are in the average particle size 
range of 278 to 386 µm. The particle size distribution is independent of the formulation 
and is dependent more on the process followed.
FORMULATION MEAN PARTICLE SIZE( D90) (µm)
F1 355.86
F2 344.86
F3 278.98
F4 330.77
F5 357.29
F6 288.86
F7 386.55
F8 289.26
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Shape and surface morphology
                       Surface morphology and internal cross sectional structure of the Floating 
Microcapsules were investigated with Scanning Electron Microscope.SEM 
photomicrographs of the blank Microcapsules, Optimized formulation were shown in the 
figures. The Microcapsules were smooth, spherical and discrete particles. Very less 
particulate matter of the drug were seen on the surface of the Microcapsules indicating 
uniform distribution of the drug in the polymer network.
Fig 20: SEM of blank microcapsules
Fig 21:SEM of foptima 
75
Fig 22: SEM of Foptima2
DISCUSSION:
                 The SEM  images show Spherical Microspheres with a rough and porous 
surface. The Microspheres for the scale up batch (Fig 22) shows that the Microspheres 
obtained for the scale up batch are reproducible in surface characteristics.
DRUG LOADING AND ENTRAPMENT EFFICIENCY: 
        Table10: ENTRAPMENT EFFICIENCIES OF THE FORMULATIONS.
FORMULATION
ENTRAPMENT 
EFFICIENCY
F1 60.39
F2 68.58
F3 88.00
F4 78.61
F5 69.97
F6 70.41
F7 85.27
F8 88.70
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Figure 23:Entrapment Efficiency
DISCUSSION:
                 The drug Entrappment Efficiency is dependent on the level of Ethyl cellulose 
in the formula. For formulations with Ethyl cellulose is 500 mg, the Entrappment 
Efficiency is> 80%. For formulations with Ethyl cellulose levels at 200 mg, the 
Entrapment Efficiency is around 6o to 75%
IN VITRO BUOYANCY STUDIES
The duration of floatation for all the batches of Microballons was evaluated as follows:
 Quantity of Microballons equivalent to 100 mg of Ziprasidone 
Hydrochloride was accurately weighed out for each batch.
 This amount was added to a 500 ml glass beaker containing 250 ml of 
0.1N HCL(medium). A three blade remi stirrer was fitted into the medium.
 The medium was stirred at 50 rpm for a period of 12 hours
 The behavior of the Microcapsules were observed at 2, 4, 8 and 12 hours 
interval and the visual observations were noted.
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Table 11:IN VITRO BUOYANCY STUDIES
S. No. Formulation 
No.
Time (Hours)
0 2 4 8 12
1 F1 Floating 
without 
clumping
Floating 
without 
clumping
Floating 
without 
clumping
Floating 
without 
clumping
The
clumps of 
ethyl 
cellulose 
are formed 
on the 
surface
2 F2 Floating 
without 
clumping
Floating 
without 
clumping
Floating 
without 
clumping
Floating 
without 
clumping
The 
clumps of 
ethyl 
cellulose 
are formed 
on the 
surface
3 F3 Floating 
without 
clumping
Floating 
without 
clumping
Floating 
without 
clumping
Floating 
without 
clumping
Floating 
without 
clumping
4 F4 Floating 
without 
clumping
Floating 
without 
clumping
Floating 
without 
clumping
Floating 
without 
clumping
Floating 
without 
clumping
5 F5 Floating 
without 
clumping
Floating 
without 
clumping
The 
clumps of 
ethyl 
cellulose 
are 
formed 
The 
clumps of 
ethyl 
cellulose 
are 
formed 
The 
clumps of 
ethyl 
cellulose 
are formed 
on the 
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on the 
surface
on the 
surface
surface
6 F6 Floating 
without 
clumping
Floating 
without 
clumping
The 
clumps of 
EC are 
formed 
on the 
surface
The 
clumps of 
EC are 
formed 
on the 
surface
The 
clumps of 
ethyl 
cellulose 
are formed 
on the 
surface
7 F7 Floating 
without 
clumping
Floating 
without 
clumping
Floating 
without 
clumping
Floating 
without 
clumping
The 
clumps of 
ethyl 
cellulose 
are formed 
on the 
surface
8 F8 Floating 
without 
clumping
Floating 
without 
clumping
Floating 
without 
clumping
Floating 
without 
clumping
The 
clumps of 
ethyl 
cellulose 
are formed 
on 
thsurface
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IN-VITRO DISSOLUTION STUDIES: 
                     In vitro release study of Ziprasidone Hydrochloride Floating Microspheres 
were performed in the following pH media (pH 1.2) at 370C ±0.50C.
 In vitro dissolution testing was conducted on microcapsules equivalent to 
100 mg of Ziprasidone Hydrochloride.
 Microcapsules were filled in hard gelatin capsules shells
 USP Type I apparatus was used
 Media 900 ml 0.1N HCLwith 0.5% Sodium Lauryl Sulphate
 RPM: 50 rpm
 Time points: 0. 0.5, 1, 2, 4 and 8 hours
 Estimation by UV Spectrophotometry. 
 The in vitro release profile of Ziprasidone Hydrochloride Floating
Microspheres were shown In table 12
Table 12: DISSOLUTION PROFILE AT pH 1.2
TIME
DISSOLUTION PROFILE FOR 
ZIPRASIDONE HCL FLOATING 
MICROCAPSULES
LLL LLH LHL LHH HLL HLH HHL HHH
F1 F2 F3 F4 F5 F6 F7 F8
0 0 0 0 0 0 0 0 0
0.5 5.35 7.23 1.09 1.23 30.87 38.32 1.32 5.54
1 9.87 12.45 3.44 5.89 68.61 82.452 5.29 10.88
2 14.79 38.67 10.08 12.44 80.45 88.76 18.35 30.49
4 35.32 70.34 35.85 40.87 88.26 90.12 28.44 60.7
8 80.29 90.35 60.43 68.64 90.23 93.5 78.48 88.58
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Figure24:Dissloution profile of Ziprasidone Hydrochloride
DISCUSSION:
 The drug release rate and extent is dependent of the ratio of the drug and 
ethyl cellulose as well as the pore former concentration.
 For formulations with Drug to polymer ratio (F1, F2, F7 and F8), the 
release is dependent on concentration of HPMC (faster release for higher 
HPMC levels)
 For formulations with drug to polymer ratio , F3 and F4 the release is very 
slow (< 70% in 8 hours)
 For formulations with drug to polymer ratio , F5 and F6 the release is very 
fast (> 80% in 2 hours)
Release kinetics:
                  Korsemeyer-Peppas Model indicates that the release mechanism is not 
well known or more than one type of release phenomena could be involved. The 
‘n’ value could be used to characterize different release mechanisms as
:
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Table 13: RELEASE EXPONENT (N) VALUES AND DRUG TRANSPORT    
MECHANISM
Release exponent (n) Drug Transport Mechanism
0.5
Fickian diffusion (Higuchi 
Matrix)
0.45< n< 0.89 Non- Fickian diffusion
0.89 Case II transport
Higher than 0.89 Super case II transport
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Figure 14:Release Rate of  Ziprasidone Hydrochloride from Formulations (F1-F8)
Formulation R2 Peppas
n
Zero First Higuchi Peppas
F1 0.9981 0.9646 0.9272 0.9991 0.943
F2 0.9080 0.9964 0.9524 0.9659 0.874
F3 0.9867 0.9800 0.8689 0.9885 1.353
F4 0.9876 0.9918 0.9165 0.9915 1.146
F5 0.5225 0.9057 0.7911 0.7384 0.322
F6 0.4127 0.7461 0.6958 0.6188 0.244
F7 0.9981 0.9491 0.8834 0.9949 1.091
F8 0.9420 0.9946 0.9491 0.9803 0.927
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          In order to understand the mechanism of drug release from the Microspheres, the in 
vitro drug release data were fitted to Korsmeyer and Peppas release model and 
interpretation of release exponent values enlightens in understanding the release 
mechanism from the dosage form. The release exponents thus obtained were from 0.874 -
1.353 for the formulations F1- F4 and F7 - F8..
                      Based on these values we can say that formulations exhibited super case-ii 
transport. The release exponents formulations F6 and F5 was found to be 0.244 and 
0.322Based on these values we can say that formulations exhibited anomalous diffusion 
mechanism (Non Fickian Transport).
                       The formulations F1 and F3 showed higher r values for Korsmeyer and 
Peppas release plot indicating that the drug release from these formulations exhibited 
Anomalous Diffusion Mechanism. Also the remaining formulations showed higher r 
values for first order plot indicating that the drug release followed first order kinetics and 
also the drug release from the microspheres were by both diffusion and erosion
DISCUSSION:
 The release of Ziprasidone Hydrochloride at 1 hour and 8 hours time points were 
taken as the measurable parameters for running the DOE experiments . The 1 hour 
time point indicates the rate of release and the 8 hours time point is a measure of the 
enxtent of the release. The following are
for both 1 hour and 8 hours, there is a strong positive interaction between the drug 
to Ethyl cellulose ratio and the rate and extrent of drug release.
 Hydroxy Propyl Methyl Cellulose 6 cps which is added as the pore former, does not 
show either positive or negative impact on drug release. However, for formulations 
having Hydroxy propyl Methyl Cellulose in higher concentrations, the drug release 
is more complete (at higher Ethyl Cellulose level) than formulations having low 
level of Hydroxh Propyl Methyl Cellulose
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 The design space for the Ziprasidone Hydrochloride, Ethyl Cellulose and Hydroxy 
Propyl Methyl Cellulose is defined as per Table 11
 In order to confirm the design space, 3 formulations within the space were fabricated 
at a larger scale and evaluted for dissolution profile.
 These formulations were subjected to accelerated stability studies after filling into 
hard gelatin capsules shells.
Figure 25:DOE Charts
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               The DOE charts were obtained by feeding the entrapment efficiency data in to 
the DOE Pro XL software and the design space values were calculated using residual 
analysis.Y-hat contour plots,Y-hat surface plots,Y- hat interaction plots were plotted for  
independent variables that is Ziprasidone Hydrochloride,Ethyl Cellulose and Hydroxy 
Propyl Methyl Cellulose. The charts reveal that there is strong positive interaction 
between Ziprasidone Hydrochloride and Ethyl Cellulose and Hydroxy Propyl Methyl 
Cellulose.
                  By considering the below observations an optimized formula was designed, 
formulated and evaluated. 
                  The Y-Contour plotsspecify the design space within which each formulation 
component can be varied without compromising on the entrapment efficiencies. The 
design space values are tabulated in Table 15
Table 15: Design Space Range for entrappment  efficiency > 77% for
                     Ziprasidone Hydrochloride
S.No Indgredients (mg/unit) Lower Limit Higher Limit 
1 Ziprasidone 
Hydrochloride
50 70 
2 Ethyl Cellulose 7cps 145 150 
3 HPMC 6 cps 0.4 2.0 
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Based on the values given in the above table an F optimum formulation was fabricated 
and evaluated for entrapment efficiency.Formulation composition and Entrapment 
efficiency achieved are given in Table 16. 
Table 16: Composition and Entrapment efficiency of Optimised Formulation
CHARCTERSTICS F OPTIMA-1 F OPTIMA-2 F-OPTIMA-3
YIELD(%w/w/ 74.82 79.45 77.92
ASSAY(mg 
Ziprasidone 
HCl/100mg)
25.357 24.734 28.799
ENTRAPMENT 
EFFICIENCY
87.39 88.58 78.00
S.No
Formulation 
No.
Formulation 
Ingredients
Mg/unit
1 Foptima 1 ZiprasidoneHCl 50
EC 145
HPMC 0.2
2 Foptima 2 ZiprasidoneHCl 60
EC 147
HPMC 1.0
3 Foptima 3 ZiprasidoneHCl 70
EC 150
HPMC 2
4 Tween 80 (ml) 1
5 IPA (ml)
6 DCM (ml)
7 Water (ml)
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AVG.PARTICLE 
SIZE 
DISTRIBUTION 
(D90 ,MICRONS)
355.86 344.25 278.98
DISCUSSION:
              The process used for the initial batches, is reproducible and scalable. The rsults 
for yield Assay, Entrappment efficeinncy and Particle size distribution are reproducible. 
This indicates that the selected Solvent Evaopration for Techinque is suitable formulation 
of Floating Microspheres.
Table17:DISOLUTION PROFILE FOR OPTIMIZED FOLUMULATION OF 
ZIPRASIDONE HCL MICROBALLONS
TIME Foptima1 Foptima2 Foptima3
0 0 0 0
0.5 6.35 9.23 7.54
1 11.87 18.45 15.88
2 24.79 28.67 33.49
4 65.32 75.34 67.7
8 85.29 94.35 90.58
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Figure26:DISSOLUTION PROFILE FOR OPTIMIZED FORMULATIONS
DISCUSSION:
                 The dissolution profile for all three formulations fabricated within the design 
space are showing Matching values. This indicates that any formulation fabricated within 
the design space will give a product having dissolution profile in a very narrow range of 
acceptability.
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Table18:Release rate of Ziprasidone Hydrochloride from optimized formulations
Figure 27: RELEASE RATE OF ZIPRASIDONE HCL FROM F-OPTIMA1 
FORMULATION 
Formulation R2 Peppas
n
Zero First Higuchi Peppas
F-optima1 0.9377 0.9843 0.9195 0.9797 0.996
F-optima2 0.9241 0.9846 0.9281 0.9746 0.874
F-optima3 0.9420 0.9946 0.9491 0.9803 0.927
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Figure28:RELEASE RATE OF ZIPRASIDONE HCL FROM  F-OPTIMA2  
FORMULATION
Figure29:RELEASE RATE OF ZIPRASIDONE HCL FROM  F-OPTIMA3 
FORMULATION
                            In order to understand the mechanism of drug release from the
microsphers, the in vitro drug release data of the optimized formulations were fitted to 
Korsmeyer and Peppas release model and interpretation of release exponent values 
enlightens in understanding the release mechanism from the dosage form. The release 
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exponents thus obtained were from 0.874,0.996 and 0.927. Based on these values we can
say that formulations exhibited super case 
                      All the optimized formulations showed higher R values for first order plot 
indicating that the drug release followed first order kinetics and also the drug release 
from microspheres were by both diffusion and erosion.
ACCELERATED STABILITY STUDIES FOR ZIPRASIDONE HCL FLOATING 
MICROCAPSULES
                      Three batches of optimized formulations were fabricated as per the table 19 
below:
S.no Formulation No. Ingredients mg/unit g/500 units
1 Foptima 1 ZiprasidoneHCl 50 25
EC 145 72.5
HPMC 0.2 0.1
2 Foptima 2 ZiprasidoneHCl 60 30
EC 147 73.5
HPMC 1.0 0.5
3 Foptima 3 ZiprasidoneHCl 70 35
EC 150 75
HPMC 2 1.0
Tween 80 (ml) 100
IPA (ml) 500
DCM (ml) 500
Water (ml) 5000
                      
                      The batches were fabricated by the process described in Materials and 
Methods. The process was reproducible at this scale.
                       These batches were evaluated for Assay, % Entrapment Efficiency , Flow 
properties and In vitro dissolution profile in 0.1N HCL. The results of the physical 
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properties, Assay and% Entrapment Efficiency are given in Table. The In vitro 
dissolution profile for these 3 batches is given in below Table.
                       The Microcapsules were filled at level equivalent to 100 mg drug content 
in size ‘1’ hard gelatin capsules shells, packed in 90 cc HDPE container and subjected to 
Accelerated Stability Studies at 4O0C/75% RH stability conditions. Samples were 
withdrawn at 1Month, 2Month and 3Month intervals and evaluated for assay and in vitro 
dissolution testing. The results are given in Table 20
Table 20:ASSAY AND IN VITRO DISSLOUTION TESTING
Tests Specificati
ons
F optima1 F2 F3
1M 2M 3M 1M 2M 3M 1M 2M 3M
Description White  to 
off white 
microcaps
ules filled 
in 
transperan
t size ‘1’ 
capsules 
shells
Com
plies
Comp
lies
Comp
lies
Comp
lies
Comp
lies
Comp
lies
Comp
lies
Comp
lies
Comp
lies
Assay 
(mg/100mg)
between 20 
to 35 
mg/100 mg
25.40 24.98 25.00 24.77 24.89 24.64 28.79 27.68 27.54
Targeted 
Dissolution 
profile
0 0 0 0 0 0 0 0 0 0 0
0.5 NMT 10% 6.00 5.99 6.28 8,76 8.57 8.01 7.54 7.00 7.04
1.0 10 – 20% 10.97 10.00 11.43 15,88 13.09 15.54 17.28 16.43 15.98
2.0 15 – 40% 24.78 23.51 27.84 25.32 27.12 28.25 34.08 32.15 35.04
4.0 55 – 75% 63,37 60.43 65.33 70.66 73.07 71.17 72.91 70.69 71.45
8.0 NLT80% 
(Q)
87.98 87.09 88.96 90.42 93.22 95,24 92.83 89.09 93.65
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SUMMARY AND CONCLUSION
               The hydro dynamically balanced modified release dosage form of Ziprasidone
Hydrochloride as targeted to be developed using a unique Microballons platform
               Microballons were formulated using Ethyl Cellulose 7 cps as the controlled 
release polymer, Hydroxy Propyl Methyl Cellulose 6 cps as the pore former and 
Dichloromethane and Isopropyl alcohol as solvents for the drug and polymers. Water 
with 1% Tween 80 was used as the continuous phase.
               The formulation was optimized by using statistically designed 23 Design of 
experiments. The Drug content, Entrapment efficiency, Particle size distribution and In 
vitro dissolution profile were the measurable parameters.
               The formulation showed that the Drug content, Entrapment efficiency and  
Particle size distribution were not the dependent variable. There was no significant 
differences in any of the above parameters in all the 8 experimental runs
.
                However, in case of the In vitro dissolution studies, the rate and extent of the 
release profile was strongly dependent of the drug and polymer ratio as well as on the 
pore former concentration.
                A design space was defined within which an optimum formulation could be 
successfully achieved with the in vitro release profile matching to the Target product 
profile.
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The defined design space is as per the Table 15
S. No Formulation Ingredient Low Level (mg/unit) High Level
(mg/ unit)
1 Ziprasidone Hydrochloride 50 70
2 Ethyl Cellulose 7 cps 145 150
3 Hydroxy Propyl Methyl Cellulose
6 cps
0.4 2.0
                  A formulation (F optima) was scaled up to 500 units within the design space, 
filled into size ‘1’ Hard gelatin capsules, packed in 90 cc HDPE container and exposed to 
accelerated stability condition of 40◦C/ 75% RH. Samples were withdrawn at 1Month, 
2Month and 3Month intervals and analysed for Assay and In vitro drug profiling. 
                  The stability data does not indicate any significant change in the formulation 
behavior over the 3 months accelerated  condition.
                  This formulation is selected for further scale up and process optimization.
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